Indonesia has achieved a remarkable increase in drug-susceptible tuberculosis (DS-TB) notification in 2022 and 2023 after a significant drop in 2020-/2021 due to COVID. In 2023, the country has notified the highest ever number of patients with DSTB - 821,200 persons (77% of incidents) 1077% increase compared to pre-COVID notifications (tbdiah.org). However, during the same year, almost 100,000 notified patients didn't initiate treatment, or their treatment status is not known due to different reasons.
The DS-TB treatment gap is not a new phenomenon. The magnitude however is evolving, e.g., the gap was 8% in 2021 but became 12% in 2023. Only 79% of patients from private physicians, 82% from private clinics, 89% in government clinics, 87% in private hospitals, 86% in public hospitals, and 92% patients in Puskesmas were enrolled in DS-TB treatment in 2023. People diagnosed with TB who are not treated may develop worsen conditions and continue transmission to their household and close contacts.
Indonesia has strengthened public-private mix strategy in TB program implementation, which enabled referrals between healthcare facilities particularly for those with limited diagnostic tools availability and capacity to provide treatment to nearest DOTS facilities that provide quality and standardized care. Unfortunately, even with successful referral for accurate diagnosis, not all people with TB initiated treatment. The main objectives is are to find out what are the causes for the gaps; why, where and when they are happening.
While improving TB screening, diagnosis and notification are critical steps, ensuring everyone diagnosed receives appropriate and timely treatment is very important. The gap between notification and treatment could arise due to different reasons in service delivery, access and barriers to care, and issues in the health systems including sources, quality and completeness of data. An assessment to better understand the root causes and mitigating them would be urgently needed. Therefore, this assessment aims to examine the process, barriers, and good practices in treatment initiation including the vertical and horizontal referrals between healthcare facilities.
The assessment approach could be streamlined balancing scientific rigor and pragmatic and time needed.
The assessment would use both qualitative and quantitative approaches. These include desk reviews at the beginning of the assessment, development of a data collection tool/questionnaires, plan for data collection including site visits and data analysis.
Description of works and responsibilities of the Assistant Consultant :
- Work in close collaboration with Public Health Expert to ensure all the tasks for DS-TB enrolment gap assessment are done on time
- Collect and process TB data related to DS-TB enrolment gap assessment
- Provide clean TB data for further analysis result by consultant team (public health expert and data analyst) in order to develop desk review report.
- Prepare and support the administration task needed by the consultant team, such as drafting letter, Minutes of Meeting, travel request, schedule and coordinate meetings and data collection schedules.
- Participate in meetings and regular communication with NTP and USAID-BEBAS TB
Qualifications
Required Education:
Bachelor's degree in public health (epidemiology and biostatistics preferred)
Experience:
- Relevant experience (at least 3-5 years);
- Proficiency in data analysis software (e.g., SPSS) and qualitative analysis tools (e.g., NVivo).
- Strong research skills, including experience in literature reviews, and data collection.
- Excellent attention to detail and accuracy when processing information
- Ability to work under strict deadlines
- Ability to adapt to changing plans and requirements.
- Ability to work effectively as part of a team and collaborate with colleagues from diverse backgrounds
- Excellent written and verbal communication skills, with the ability to communicate findings and recommendations clearly and effectively.
- Cultural competence and sensitivity to work in diverse settings and engage with communities and stakeholders respectfully.
- Fluency in relevant languages (Bahasa Indonesia and English)
MSH is an equal opportunity employer and will not discriminate against any employee or applicant for employment on the basis of race, color, sex, sexual orientation, gender or gender identity, religion, creed, citizenship, national origin, age, veteran status, or disability unrelated to job requirements. MSH will take affirmative action to ensure that qualified applicants are employed and that employees are treated without regard to their race, age, color, religion, sex, sexual orientation, gender identity, national origin, veteran and disability status. In compliance with U.S. Department of Labor Executive Order 11246, Section 503 of the Rehabilitation Act, and Section 4212 of the Vietnam Era Readjustment Assistance Act, MSH has developed and maintains an affirmative action program and plan.
EEO is the Law - English
EEO is the Law - Spanish
Pay Transparency Nondiscrimination Poster
Know Your Rights - Workplace Discrimination is Illegal
Family and Medical Leave Act (FMLA)
Employee Polygraph Protection Act
MSH EEO-AA Policy
